GlassScriptPhysician profile
Steven Ira Dyckman
NPI 1396864385
$53,180.80
in general payments reported to CMS, 2019-2025
28 companies · $4,487 in 2025
The $4,487 reported for 2025 was more than what 97% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,876 · 2020: $2,376 · 2021: $2,936 · 2022: $4,368 · 2023: $18K · 2024: $18K · 2025: $4,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $4,891 · Consulting Fee: $4,160 · Travel and Lodging: $61.57 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,500.00 |
| Food and Beverage | $4,890.93 |
| Consulting Fee | $4,160.00 |
| Travel and Lodging | $61.57 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,637.36 | 2021-2025 | Vraylar |
| Corium, LLC | $4,447.50 | 2022-2025 | Azstarys, Azstarys |
| Allergan, INC. | $3,376.22 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $1,419.16 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $1,168.36 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $950.26 | 2019-2025 | Rexulti, Abilify Mycite |
| Takeda Pharmaceuticals U.S.A., INC. | $799.37 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $630.31 | 2021-2025 | Caplyta |
| Lundbeck LLC | $467.80 | 2019-2025 | Rexulti |
| Tris Pharma INC | $393.05 | 2019-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $307.05 | 2023-2024 | Auvelity, Sunosi |
| Neos Therapeutics, LP | $260.92 | 2019-2022 | |
| Alkermes, INC. | $217.21 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $198.95 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $153.86 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $152.45 | 2020-2025 | Aplenzin, Wellbutrin |
| Adlon Therapeutics L.P. | $89.63 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $83.43 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $78.33 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $74.32 | 2024-2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $62.91 | 2019-2022 | |
| Eisai INC. | $53.12 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $43.73 | 2024 | Relexxii |
| Janssen Pharmaceuticals, INC | $40.69 | 2019-2025 | Spravato |
| Rhodes Pharmaceuticals L.P. | $27.94 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.44 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.94 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Dyckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.